MX354125B - A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease. - Google Patents

A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.

Info

Publication number
MX354125B
MX354125B MX2013007622A MX2013007622A MX354125B MX 354125 B MX354125 B MX 354125B MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 354125 B MX354125 B MX 354125B
Authority
MX
Mexico
Prior art keywords
opioid
parkinson
disease
treatment
combination
Prior art date
Application number
MX2013007622A
Other languages
Spanish (es)
Other versions
MX2013007622A (en
Inventor
Michael Hopp
Claudia Trenkwalder
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP10197210 priority Critical
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Priority to PCT/EP2011/074103 priority patent/WO2012089738A1/en
Publication of MX2013007622A publication Critical patent/MX2013007622A/en
Publication of MX354125B publication Critical patent/MX354125B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating

Abstract

The present invention provides a pharmaceutical dosage form comprising an opioid agonist and an opioid antagonist for use in the treatment of Parkinson's disease. The present invention also refers to the use of an opioid agonist and an opioid antagonist in such a dosage form.
MX2013007622A 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease. MX354125B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10197210 2010-12-28
PCT/EP2011/074103 WO2012089738A1 (en) 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
MX2013007622A MX2013007622A (en) 2013-12-06
MX354125B true MX354125B (en) 2018-02-14

Family

ID=43903970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007622A MX354125B (en) 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.

Country Status (19)

Country Link
US (1) US20140037729A1 (en)
EP (1) EP2658523A1 (en)
JP (2) JP5864606B2 (en)
KR (2) KR101618929B1 (en)
CN (1) CN103347495B (en)
AR (1) AR084620A1 (en)
AU (1) AU2011351447B2 (en)
BR (1) BR112013016862A2 (en)
CA (1) CA2822528C (en)
CL (1) CL2013001943A1 (en)
EA (1) EA025747B1 (en)
MX (1) MX354125B (en)
MY (1) MY162895A (en)
NZ (1) NZ612837A (en)
SG (1) SG191208A1 (en)
TW (2) TWI554271B (en)
UA (1) UA109301C2 (en)
WO (1) WO2012089738A1 (en)
ZA (1) ZA201304303B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002881B (en) 2010-05-10 2015-09-02 欧洲凯尔特公司 Compositions containing the active agent particles and the additional active agent
BR112012028788A2 (en) 2010-05-10 2016-07-19 Euro Celtique Sa manufacturing granules without active
MX354125B (en) * 2010-12-28 2018-02-14 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9289423B2 (en) 2011-04-29 2016-03-22 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
JP2016525138A (en) * 2013-07-23 2016-08-22 ユーロ−セルティーク エス.エイ. The combination of oxycodone and naloxone for use in the treatment of pain in patients suffering from diseases increase the risk for diseases and / or Enterobacteriaceae migration results in pain and intestinal Disconnect bio cis
EA030310B1 (en) 2013-11-13 2018-07-31 Эро-Селтик С.А. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
WO2015187932A1 (en) * 2014-06-04 2015-12-10 Mentinova Inc. Compositions and methods of reducing sedation
US9765027B2 (en) 2014-08-22 2017-09-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
CA2974055A1 (en) * 2015-01-23 2016-07-28 Euro-Celtique S.A. A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk forintestinal bacterial translocation
WO2016190766A1 (en) * 2015-05-26 2016-12-01 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
US20180104236A1 (en) * 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
IL151057D0 (en) * 2000-02-08 2003-04-10 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
WO2002005647A1 (en) * 2000-07-13 2002-01-24 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070232638A1 (en) * 2006-04-03 2007-10-04 Howard Brooks-Korn Opiopathies
PE04222011A1 (en) * 2008-07-07 2011-07-01 Euro Celtique Sa pharmaceutical composition comprising opioid antagonists
MY152279A (en) * 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
MX354125B (en) * 2010-12-28 2018-02-14 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.

Also Published As

Publication number Publication date
TW201302199A (en) 2013-01-16
CA2822528C (en) 2017-07-18
CN103347495B (en) 2017-06-20
AR084620A1 (en) 2013-05-29
MY162895A (en) 2017-07-31
KR101632858B1 (en) 2016-06-22
JP6074003B2 (en) 2017-02-01
AU2011351447B2 (en) 2016-02-25
CL2013001943A1 (en) 2013-11-29
UA109301C2 (en) 2015-08-10
NZ612837A (en) 2014-11-28
TW201628618A (en) 2016-08-16
JP2016040268A (en) 2016-03-24
KR20150076262A (en) 2015-07-06
TWI554271B (en) 2016-10-21
JP2014501268A (en) 2014-01-20
JP5864606B2 (en) 2016-02-17
ZA201304303B (en) 2014-02-26
US20140037729A1 (en) 2014-02-06
AU2011351447A1 (en) 2013-07-25
EP2658523A1 (en) 2013-11-06
EA025747B1 (en) 2017-01-30
MX2013007622A (en) 2013-12-06
SG191208A1 (en) 2013-07-31
BR112013016862A2 (en) 2016-10-04
KR101618929B1 (en) 2016-05-09
KR20130106431A (en) 2013-09-27
WO2012089738A1 (en) 2012-07-05
EA201390977A1 (en) 2013-12-30
CA2822528A1 (en) 2012-07-05
CN103347495A (en) 2013-10-09

Similar Documents

Publication Publication Date Title
TWI595906B (en) Medicament delivery device
GB2479953B (en) Drug delivery device
TWI415849B (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
ZA201209381B (en) The use of inhibitors of bruton's tyrosine kinase (btk)
EP2542074A4 (en) Combination pharmaceutical agents as inhibitors of hcv replication
HRP20150963T1 (en) Drug delivery device
IL207128A (en) Pharmaceutical dosage form and uses thereof
HK1205690A1 (en) Pharmaceutical composition and administration thereof
IL223783A (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
EP2544741A4 (en) Medicament delivery device
TW201204714A (en) New compounds
IL219910A (en) Device and method for delivery of two or more drug agents
MX2016007851A (en) Peptidomimetic compounds and antibody-drug conjugates thereof.
TW201329071A (en) Heterocyclic inhibitors of glutaminase
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
EP2528441A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2012012771A (en) Combination therapy.
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
TW201206917A (en) Pharmaceutical compositions
LT2838512T (en) Tamper resistant and dose-dumping resistant pharmaceutical dosage form
TW201323424A (en) Compounds
IL214572A (en) Derivatives of substituted 9-alkylaryl- 9h- purin-6-ylamine, pharmaceutical compositions comprising them and such compounds being toll-like receptor antagonists for use in treating diseases
TW201116278A (en) Compounds as lysophosphatidic acid receptor antagonists
TWI405757B (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX357496B (en) Fluorinated estrogen receptor modulators and uses thereof.

Legal Events

Date Code Title Description
FG Grant or registration